Key facts
- Endogenex’s last known valuation is $218.0M (Mar 2026).
- It has raised $190.4M across 3 recorded rounds; the latest was Later Stage VC ($69.6M) in Jun 2024.
- Notable investors include Hatteras Venture Partners, Mayo Clinic Ventures, Arboretum Ventures, Longitude Capital, Fourth Element Capital — 11 tracked in total.
- Endogenex has filed 3 Form Ds with the SEC since 2023, most recently Jun 2024 ($69.6M sold to 11 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Endogenex
Funding rounds
3 roundsAbout Endogenex
Developer of a medical device system designed to improve metabolic function in individuals with diabetes by resetting metabolic signalling in the small intestine. The company's device delivers controlled, non-thermal pulsed electric fields through an endoscopic procedure to promote duodenal tissue regeneration, enabling patients with type 2 diabetes to better manage blood glucose and support metabolic health.
- Sector
- Healthcare
- HQ
- Plymouth, MN, United States
- Founded
- 2017
- Employees
- 28
- Website
- endogenex.com/
- Ownership
- Privately Held (backing)
Endogenex doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Endogenex shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Endogenex in its N-PORT filings yet. We sweep new filings monthly.